<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Munich_Demonstrate skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Munich/Demonstrate</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P><TITLE>Phactory</TITLE></P><H5 class="d-inline ml-3">Phactory</H5><DIV class="collapse navbar-collapse justify-content-around" id="collapsibleNavbar"><UL class="navbar-nav"><LI id="homeButton" class="nav-item mx-3"><A class="nav-link" href="https://2018.igem.org/Team:Munich">HOME</A></LI><LI class="nav-item dropdown mx-3"><A class="nav-link dropdown-toggle" href="#" id="navbardrop" data-toggle="dropdown">
                            TEAM
                        </A><DIV class="dropdown-menu"><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Team">Team Members</A><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Collaborations">Collaborations</A><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Sponsors">Sponsors</A><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Attributions">Attributions</A></DIV></LI><LI class="nav-item dropdown mx-3"><A class="nav-link dropdown-toggle" href="#" id="navbardrop" data-toggle="dropdown">
                            PROJECT
                        </A><DIV class="dropdown-menu"><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Description">Description</A><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Design">Design</A><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Notebook">Notebook</A><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Protocols">Protocols</A><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/InterLab">InterLab</A><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Model">Model</A><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Results">Results</A><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Demonstrate">Demonstrate</A></DIV></LI><LI class="nav-item dropdown mx-3"><A class="nav-link dropdown-toggle" href="#" id="navbardrop" data-toggle="dropdown">
                            PARTS
                        </A><DIV class="dropdown-menu"><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Parts">Parts Overview</A><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Basic_Part">Basic Parts</A><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Improve">Improved Parts</A><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Composite_Part">Composite Parts</A></DIV></LI><LI class="nav-item mx-3"><A class="nav-link" href="https://2018.igem.org/Team:Munich/Safety">SAFETY</A></LI><LI class="nav-item dropdown mx-3"><A class="nav-link dropdown-toggle" href="#" id="navbardrop" data-toggle="dropdown">
                            HUMAN PRACTICES
                        </A><DIV class="dropdown-menu"><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Human_Practices">Human Practices</A><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Public_Engagement">Education &amp; Engagement</A><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Oracoli">Oracoli</A><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/European_Meetup">European Meetup</A></DIV></LI><LI class="nav-item dropdown mx-3"><A class="nav-link dropdown-toggle" href="#" id="navbardrop" data-toggle="dropdown">
                            AWARDS
                        </A><DIV class="dropdown-menu"><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Applied_Design">Applied Design</A><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Entrepreneurship">Entrepreneurship</A><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Hardware">Hardware</A><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Measurement">Measurement</A><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Model">Model</A><A class="dropdown-item" href="https://2018.igem.org/Team:Munich/Software">Software</A></DIV></LI><LI class="nav-item mx-3"><A class="nav-link" href="https://igem.org/2018_Judging_Form?team=Munich" target="_blank">JUDGING FORM ⇗</A></LI></UL></DIV><DIV class="pictureTitle container-fluid text-center mb-0 align-items-center text-light"><DIV class="display-2 mb-0">
                     Demonstrate
                    </DIV></DIV><DIV class="phaContainer"><MAIN class="post-content"><DIV class="row"><DIV class="col-12"><H2>Phactory - A Safe Manufacturing Pipeline</H2><P>Phactory revolutionizes the production of therapeutic phages independently
      from their bacterial hosts. Each step of our bacteriophage production line
      has been optimized individually to meet Good Manufacturing Practice and
      guarantee that all safety requirements for therapeutic phages are met.
      The simplicity of Phactory enables phage assembly by
      simply adding high-purity phage genomic DNA to cell extract. This allows for
      flexible and individualized medical treatment of patients.
    </P><P>
      Maximum phage purity and high titers are ensured by filtration and
       purification steps. Furthermore, Phactory incorporates packaging of our
       assembled phages in alginate capsules for protection from gastric acid
        after oral administration and intestinal delivery.</P></DIV></DIV><H5>Safety Requirements for Therapeutic Phages</H5><DIV class="row align-items-center"><DIV class="col-6 col-md-4"><SPAN style="color: rgba(0, 158, 198,1); font-weight: bold;">Identification</SPAN></DIV><DIV class="col-6 col-md-6"><SPAN>Complete Genome, Plaque Assay</SPAN></DIV></DIV><DIV class="row align-items-center"><DIV class="col-6 col-md-4"><SPAN style="color: rgba(0, 158, 198,1); font-weight: bold;">Contamination</SPAN></DIV><DIV class="col-6 col-md-6"><SPAN>Microorganisms DNA Prophages
</SPAN></DIV></DIV><DIV class="row align-items-center"><DIV class="col-6 col-md-4"><SPAN style="color: rgba(0, 158, 198,1); font-weight: bold;">Toxicity</SPAN></DIV><DIV class="col-6 col-md-6"><SPAN>5 Endotoxin Units / kg bm</SPAN></DIV></DIV><DIV class="row align-items-center"><DIV class="col-6 col-md-4"><SPAN style="color: rgba(0, 158, 198,1); font-weight: bold;">pH</SPAN></DIV><DIV class="col-6 col-md-6"><SPAN>6.5 – 7.5</SPAN></DIV></DIV><DIV class="row align-items-center"><DIV class="col-6 col-md-4"><SPAN style="color: rgba(0, 158, 198,1); font-weight: bold;">Purity</SPAN></DIV><DIV class="col-6 col-md-6"><SPAN>Absence of Visible Particles</SPAN></DIV></DIV><DIV class="row align-items-center"><DIV class="col-6 col-md-4"><SPAN style="color: rgba(0, 158, 198,1); font-weight: bold;">Preservation</SPAN></DIV><DIV class="col-6 col-md-6"><SPAN>2 - 8°C</SPAN></DIV></DIV><H2>Identification of Bacteriophages</H2><DIV class="row align-items-center"><DIV class="col-12"><DIV class="h4">
  Plague Assay</DIV><P>
      We performed a <A href="https://2018.igem.org/Team:Munich/Software">plague assay</A>
       to determine the activity of the viable phages (titers) in our assembly batch.
      By creating serial dilutions we were able to calculate a plague forming unit / milliliter (PFU/ml) value.
      On average the titer is approximately 10<SUP>8</SUP>.
      </P><DIV class="h4">Plaque Assay of T7 phage over 6 hours</DIV><DIV class="row"><DIV class="col-12 px-0 rounded"><VIDEO autoplay="" loop="" style="width:100%;"><SOURCE src="https://static.igem.org/mediawiki/2018/4/4a/T--Munich--timelapse.mp4">
      Your browser does not support the video tag.
      </SOURCE></VIDEO></DIV></DIV><DIV class="row align-items-center"><DIV class="col-12 col-md-6"><DIV class="h4">
         Software Based Quality Control</DIV><P>
              Next Generation Sequencing by Nanopore TM made it possible to detect
              DNA impurities in our isolated bacteriophages. This is necessary to achieve
              high titers with phage assembly. With Sequ-Into we developed a custom
              <A href="https://2018.igem.org/Team:Munich/Results#title_2">open-source software tool</A>
               which simplyfies the analysis of sequencing data.
              Especially stataistical analysis of impurities are faciliated. Based on Sequ-Into
              we reduced contamination, as the improvement of our purification protocol was
              clearly detectable.
            </P></DIV></DIV><H2>Transcription-Translation System</H2><DIV class="row align-items-center"><DIV class="col-12 col-md-6"><DIV class="h4">
  High Quality Cell Extract</DIV><P>
      First we optimized our <A href="https://2018.igem.org/Team:Munich/Results#title_0">cell extract preparation protocols</A> to get highly active
      extract which is able to produce high amounts of bacteriophages.
      Specifically engineered <EM>E. coli</EM> strains are the core component for the preparation
      of cell extract with low endotoxin levels.
      We optimized our strain for therapeutic bacteriophage production by knocking
      out myristoyltransferase <EM>msbB</EM> in the host strain to disrupt the lipid A biosynthesis pathway.
      </P><DIV class="h4">
Low Endotoxin Amount</DIV><P>A LAL test was used to measure endotoxin levels. In comparison with commercially available cell extract and cell extract prepared using wild-type strains,
      the lipid A concentration could be lowered to a fraction of 2%.</P><DIV class="h4">
Physiological pH Range</DIV><P>We have approved that the assembled phage solution has a physiological pH to ensure the requirement of the correct pH range for therapeutic phages.</P></DIV><DIV class="col-12 col-md-6"><FIGURE class="figure"><FIGCAPTION class="figure-caption">Endotoxin content in different cell-extracts determined by LAL-Test. Error bars indicate standard deviation of the measured plateau values. Error bars indicate SD.</FIGCAPTION></FIGURE></DIV></DIV><DIV class="row"><DIV class="col-12 px-0 rounded"><VIDEO controls="" style="width:100%;"><SOURCE src="https://static.igem.org/mediawiki/2018/1/15/T--Munich--TXTL_DEMO.mov">
Your browser does not support the video tag.
</SOURCE></VIDEO></DIV></DIV><DIV class="row align-items-center"><DIV class="col-12 col-md-8"><DIV class="h4">Preservation of Cell Extract
</DIV><P>Cell extract can be stored and shipped at room temperature if the samples are prepared by
      <A href="https://2018.igem.org/Team:Munich/Results#title_0">lyophilization</A>. To make our cell extract accessible to everyone everywhere, we seeled to ensure long term storage and shipping at room temperature. Therefore we created lyophilized cell extract. The results show, that the tested samples retained 70% and 90% of expression quality respectively after lyophilization. </P><P>Furthermore, we tested the functionality of phages assembled in our home made cell extract after lyophilization and found functional phages afterwards.</P></DIV><DIV class="col-12 col-md-4"><FIGURE class="figure"><FIGCAPTION class="figure-caption">Our two tested samples of cell extract retained 70 and 90 % of expression quality respectively after lyophilization.</FIGCAPTION></FIGURE></DIV></DIV><H2>Phage Assembly</H2><DIV class="row"><DIV class="col-12"><P>The simplicity of Phactory offers the possibility of producing phages simply by adding the specific phage DNA to the TX-TL machinery. Moreover, Phactory yields excellent titers of assembled phages by far higher as required for therapeutic use.</P></DIV></DIV><DIV class="row align-items-center"><DIV class="col-12 col-md-8"><DIV class="h4">
High Titer</DIV><P>Phactory makes high yield of phages of up to 10<SUP>12</SUP> PFU/mL in a
       small reaction volume of 9 µL possible. Because we are using an
       <EM>E.coli</EM> based cell extract we avoid biohazardous pathogens
       traditionally necessary for therapeutic phage production. <A href="https://2018.igem.org/Team:Munich/Results#title_1">Bacteriophages can be assembled independent of the living host.</A></P></DIV><DIV class="col-12 col-md-4"><FIGURE class="figure"><FIGCAPTION class="figure-caption"> Overview of the successfully assembled phages. MS2 (RNA-phage), T4 (DNA phage), T5 (DNA phage), T7 (DNA phage), CLB-P2 (clinically relevant), CLB-P2 (clinically relevant), GEC-3S P2 (clinically relevant).</FIGCAPTION></FIGURE></DIV></DIV><DIV class="row align-items-center"><DIV class="col-12 col-md-8"><DIV class="h4">
High Purity</DIV><P>To fulfill the strict requirements for therapeutically used phages further purification is required to produce a high quality product.</P><P>The abscence of impurities in the phage solutions produced in Phactory was
      certified by Transmission Electron Microscopy (TEM) imaging. By ultra-filtration phages got successfully separated from submolecular content.</P></DIV><DIV class="col-12 col-md-4"><FIGURE class="figure"><FIGCAPTION class="figure-caption">TEM (Transmission Electron Microscopy) of the CLB-P3 phage</FIGCAPTION></FIGURE></DIV></DIV><DIV class="row align-items-center"><DIV class="col-12"><DIV class="h4">Packaging
  </DIV><P>Phactory yields phages with toxicity levels that allow oral administration to the patient.
      However, oral delivery requires protection of the phages from rapid degradation in the acidic gastric juice.
      Therefore, we <A href="https://2018.igem.org/Team:Munich/Results#title_4">encapsulated</A> our phages in alginate. This protects our phages successfully until release into the gastric system.
      We were able to prove functionality of encapsulated and released phages. </P></DIV></DIV><DIV class="row align-items-center"><DIV class="col-12 col-md-4"><FIGURE class="figure"><FIGCAPTION class="figure-caption">Animated Zoom Through Z-Stack</FIGCAPTION></FIGURE></DIV><DIV class="col-12 col-md-4"><FIGURE class="figure"><FIGCAPTION class="figure-caption">Non-encapsulated phages are highly degraded within an hour in simulated gastric fluid.</FIGCAPTION></FIGURE></DIV><DIV class="col-12 col-md-4"><FIGURE class="figure"><FIGCAPTION class="figure-caption">A generic square placeholder image with rounded corners in a figure. A small amount of encapsulated phages are released in SGF. In SIF, functional phages are released in high concentration.</FIGCAPTION></FIGURE></DIV></DIV><H2>Clinically Relevant Bacteriophages</H2><DIV class="row"><DIV class="col-12"><P>It was of great importance for us to demonstrate the medical relevance of bacteriophages manufactured with Phactory. We received the SEC-3S bacteriophage from the Queen Astrid Hospital as well as the P2 and P3 bacteriophages from the group of Laurent Debarbieux at the Pasteur Institute in Paris. These bacteriophages are specific for the E.Coli strain O104:H4, also known as EHEC, which caused 53 deaths during an outbreak in Germany in 2011. As indicated in <A href="https://2018.igem.org/Team:Munich/Human_Practices#clinically">the microscopy images</A>, we successfully assembled these medically relevant bacteriophages in our cell-free system.
We conducted a LAL-test and compared the results with magistral bacteriophage preparation regulations. According to these results, our bacteriophages are orally applicable. In the future we will work on reaching even higher titers with Phactory, so that we can apply more extensive purification protocols to allow intravenous application of bacteriophage therapy.</P></DIV></DIV><H3>Clinical Trial</H3><DIV class="row"><DIV class="col-12 px-0 rounded"><VIDEO controls="" style="width:100%;"><SOURCE src="https://static.igem.org/mediawiki/2018/b/b3/T--Munich--Phactory_Clinical_Trial_V2_lq.mov">
Your browser does not support the video tag.
</SOURCE></VIDEO></DIV></DIV><DIV id="phareferences" class="row"><H3>References</H3><DIV class="col-12"><OL><LI><A href="">Pirnay et al., “Quality and Safety Requirements for Sustainable Phage Therapy Products”, Pharm Res. 2015; 32: 2173–2179</A></LI></OL></DIV></DIV></DIV></DIV></MAIN></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>